ExocyTher SIGNED
Extracellular vesicle production and engineering by turbulence for fistula therapy in thermoreversible hydrogels
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ExocyTher project word cloud
Explore the words cloud of the ExocyTher project. It provides you a very rough idea of what is the project "ExocyTher" about.
Project "ExocyTher" data sheet
The following table provides information about the project.
| Coordinator |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Organization address contact info |
| Coordinator Country | France [FR] |
| Total cost | 1˙496˙094 € |
| EC max contribution | 1˙496˙094 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2019-STG |
| Funding Scheme | ERC-STG |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-06-01 to 2025-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS | FR (PARIS) | coordinator | 1˙496˙094.00 |
Map
Project objective
Extracellular vesicles (EVs) from stem cells (SCs) may recapitulate the therapeutic effect of their mother cells in regenerative medicine while mitigating risks of uncontrolled replication, differentiation and vascular occlusion, offering “off-the-shelf”, storage and shelf-life gains. Yet, the clinical translation of SC EV therapy is hampered by production, engineering and administration challenges. Building on my preliminary results, ExocyTher aims at developing SC EV therapy through: (1) standardized scalable high-yield EV production: I propose the concept of turbulence vesiculation to induce EV release from adipose SCs (ASCs) by a controlled turbulence shear stress integrated to large-scale cell culture in bioreactors; (2) optimised delivery: I propose EV administration in a synergic fistula-occlusive companion gel (injectable at <20°C and gelling at body temperature) in the attempt to fill the entire fistula tract and retain EVs at the site of interest; ExocyTher will tackle the therapy of fistulas, a major health burden related to Crohn's disease or secondary to surgery, cancer therapy or trauma, affecting millions of people in Europe with a high morbidity rate. All-in-one turbulence-triggered vesiculation and priming are expected to provide ASC EVs in high yield and with improved immunomodulatory properties specially for a more efficient therapy of inflammatory Crohn’s disease fistulas. Capitalizing on the use of a gel medical device authorized in Europe as an off-label fistula occlusive EV vehicle and considering key regulatory issues, ExocyTher will set the basis for the first clinical trial on ASC EV fistula therapy. ExocyTher concepts may be extended to other EV parent cell types or therapy indications, foreseeing a high scientific and technological impact.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXOCYTHER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EXOCYTHER" are provided by the European Opendata Portal: CORDIS opendata.